Researchers Develop Antibody Fragment That Fights Alzheimer's Disease in Mice

Trials with mice were conducted by researchers who injected a specific antibody fragment against soluble aggregates of the A peptide.

Trials with mice were conducted by researchers who injected a specific antibody fragment against soluble aggregates of the A peptide, responsible for the toxicity and cell death characteristic of Alzheimer's Disease.

The beneficial effects were seen at the behavioural, cellular and molecular levels five days after an intraperitoneal dose was administered.

Sugar variant may make a world of difference to Alzheimers disease
A novel study by Canadian researchers has revealed that variants of a sugar, is found to improve Alzheimers

Since the first case of Alzheimer's disease was described, the disease has been associated with the presence of insoluble deposits known as amyloid plaques.

The research group directed by Dr Sandra Villegas, from the Biosciences Unit of the Department of Biochemistry and Molecular Biology at the UAB, designed a recombinant antibody fragment (the single-chain variable fragment scFv-h3D6), a derivative of bapineuzumab, which only consists of the active part trapping the etiological agent of the disease: the domains of the antibody responsible for the binding of Abeta oligomers.

Scientists observed how this antibody fragment protected from cell death in human cell-cultures and described the molecular mechanism by which this antibody fragment removed the Abeta oligomers that cause the disease.

Age-Dependent Alterations Not Specific For Alzheimer's Disease
The oscillations in the microcirculation exhibit an age-dependent pattern, which is more pronounced in the forehead than in the forearm.

Researchers observed how a single injection into the abdomen of the animals and five days later, the mice reversed their levels of anxiety to normal levels and the learning and memory deficits were ameliorated.

At the molecular level, researchers demonstrated two important facts: first, the treatment cleared from the cerebral cortex the Abeta peptide oligomers, the elements causing the disease; and second, this clearence is linked to the recovery of the levels of certain apolipoproteins suspected to be the natural removers of Abeta peptide aggregates.

Risk Factors for Alzheimers Disease
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in the brain are more likely to develop Alzheimer’s disease.

The study is published in journal mAbs.

Source-ANI

Killing two birds (cholesterol and Alzheimers disease) with the same stone
New study points at possible treatment of both cholesterol and Alzheimer’s disease